methanesulfonic acid 2-(4,6-dichloro-pyrimidin-5-yl)-ethyl ester | 853680-75-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: methanesulfonic acid 2-(4,6-dichloro-pyrimidin-5-yl)-ethyl ester
• 英文别名: Methanesulfonic acid 2-(4,6-dichloro-pyrimidin-5-yl)-ethyl ester；2-(4,6-dichloropyrimidin-5-yl)ethyl methanesulfonate
• CAS: 853680-75-8
• 化学式: C₇H₈Cl₂N₂O₃S
• 分子量: 271.124
• InChiKey: ZBTBWIPPNXTLHQ-UHFFFAOYSA-N

物化性质

• 沸点：
  457.5±45.0 °C(Predicted)
• 密度：
  1.536±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  77.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methanesulfonic acid 2-(4,6-dichloro-pyrimidin-5-yl)-ethyl ester 在 potassium tert-butylate 、 三乙胺 作用下， 以 N-甲基吡咯烷酮 、 1,2-二氯乙烷 为溶剂， 反应 20.0h， 生成 4-[7-(4-methoxy-benzyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-piperazine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  [EN] AKT PROTEIN KINASE INHIBITORS
  [FR] INHIBITEURS DE LA PROTEINE KINASE AKT

  摘要：

  公开号：

  WO2005051304A3
• 作为产物：
  描述：

  1,1,2-乙烷三羧酸三乙酯 在 4-二甲氨基吡啶 sodium methylate 、 二异丁基氢化铝 、 三乙胺 、 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 甲醇 、 乙醚 、 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 24.0h， 生成 methanesulfonic acid 2-(4,6-dichloro-pyrimidin-5-yl)-ethyl ester
  参考文献：
  名称：

  [EN] AKT PROTEIN KINASE INHIBITORS
  [FR] INHIBITEURS DE LA PROTEINE KINASE AKT

  摘要：

  公开号：

  WO2005051304A3

文献信息

• AKT protein kinase inhibitors
  申请人：Mitchell S. Ian

  公开号：US20050130954A1

  公开（公告）日：2005-06-16

  The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

  本发明提供化合物，包括已解决的对映体、二对映异构体、溶剂化物和药学上可接受的盐，其包括公式：A-L-CR，其中CR是一个环核心基团，L是一个连接基团，A如此处所定义。同时提供了使用本发明化合物作为AKT蛋白激酶抑制剂和用于治疗增殖性疾病如癌症的方法。
• AKT PROTEIN KINASE INHIBITORS
  申请人：Mitchell Ian S.

  公开号：US20100168123A1

  公开（公告）日：2010-07-01

  The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

  本发明提供了化合物，包括已分离的对映体、非对映异构体、溶剂化物和药学上可接受的盐，其包括式子：A-L-CR，其中CR是一个环状核心基团，L是一个连接基团，A如上所定义。本发明还提供了使用这些化合物作为AKT蛋白激酶抑制剂和治疗增殖性疾病，如癌症的方法。
• 1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)indoline-4-carbonitrile Derivatives as Potent and Tissue Selective Androgen Receptor Modulators
  作者：Eugene L. Piatnitski Chekler、Rayomond Unwalla、Taukeer A. Khan、Raghuram S. Tangirala、Mark Johnson、Michael St. Andre、James T. Anderson、Thomas Kenney、Sue Chiparri、Chris McNally、Edward Kilbourne、Catherine Thompson、Sunil Nagpal、Gregory Weber、Scott Schelling、Jane Owens、Carl A. Morris、Dennis Powell、Patrick R. Verhoest、Adam M. Gilbert

  DOI：10.1021/jm401625b

  日期：2014.3.27

  We present a novel series of selective androgen receptor modulators (SARMs) which shows excellent biological activity and physical properties. 1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)-indoline-4-carbonitriles showed potent binding to the androgen receptor (AR) and activated AR-mediated transcription in vitro. Representative compounds demonstrated diminished activity in promoting the intramolecular interaction between the AR carboxyl (C) and amino (N) termini. This N/C-termini interaction is a biomarker assay for the undesired androgenic responses in vivo. In orchidectomized rats, daily administration of a lead compound from this series showed anabolic activity by increasing levator ani muscle weight. Importantly, minimal androgenic effects (increased tissue weights) were observed in the prostate and seminal vesicles, along with minimal repression of circulating luteinizing hormone (LH) levels and no change in the lipid and triglyceride levels. This lead compound completed a two week rat toxicology study, and was well tolerated at doses up to 100 mg/kg/day, the highest dose tested, for 14 consecutive days.
• US8680114B2
  申请人：——

  公开号：US8680114B2

  公开（公告）日：2014-03-25
• [EN] AKT PROTEIN KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PROTEINE KINASE AKT
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2005051304A3

  公开（公告）日：2006-07-27